HomeProfessionalsTiffany Shih
Print PDF
HomeProfessionalsTiffany Shih

Tiffany shih bodog casino review

Principal

Contact

  • Los Angeles

Education

    • University of California, Berkeley, Ph.D.
    • University of California, Berkeley, M.S.
    • Stanford University, B.S. (with distinction)

Tiffany Shih consults on life sciences and healthcare bodog casino review and regulatory investigations. Dr. Shih works with academic experts and attorneys and leads large teams to perform complex economic analyses on antitrust, product misrepresentation, reimbursement, and breach of contract matters in these industries.

Dr. Shih’s experience includes:

Antitrust bodog casino review and merger investigations
Product misrepresentation and product liability matters
  • Assessing the impact of pharmaceutical marketing on prescribers’ behavior and prescription drug sales
  • Analyzing pharmaceutical companies’ drug development decisions
  • Examining damages in consumer personal injury matters
  • Analyzing consumer class certification issues in product liability matters bodog casino review pharmaceutical industry
Reimbursement disputes
  • Evaluating economic issues related to risk-adjusted payments to Medicare Advantage insurers
Contract disputes
  • Addressing breach of contract issues related to pharmaceutical R&D and licensing agreements

Dr. Shih has published articles on healthcare and life sciences topics in medical and economics journals. In her research, Dr. Shih has addressed how money flows through the pharmaceutical distribution system, the economic impacts of biologic drugs policies, and the economic costs of disease.

Prior to joining Cornerstone Research, Dr. Shih worked at Precision Health Economics, where she provided business consulting services to major pharmaceutical companies.

Practices
tab
Press Release

Cornerstone Research Promotes Fourteen to Principal

Read More
Case

In re Novartis and Par Antitrust bodog casino review

Read More
Case

United States et al. v. UnitedHealth Group Incorporated et al.

Read More
Case

Cigna’s Acquisition of Express Scripts

Read More
  • “Short-term Costs of Preeclampsia to the United States Health Care System,” with W. Stevens, D. Incerti, T. Ton, H. Lee, D. Peneva, G. Macones, B. Sibai, and A. Jena, American Journal of Obstetrics and Gynecology 3, 2017.
  • “The Flow of Money Through the Pharmaceutical Distribution System,” with N. Sood, K. Van Nuys, and D. Goldman, Schaeffer Center White Paper Series, 2017.
  • “Product Safety Spillovers and Market Viability for Biologic Drugs,” with J. Romley, International Journal of Health Economics and Management 17: 2, 2017.
  • “Incremental Net Monetary Benefit of Ocrelizumab Relative to Subcutaneous Interferon b-1a,” with M. Frasco, D. Incerti, O. Diaz Espinosa, D. Vania, and N. Thomas, Journal of Medical Economics 20: 10, 2017.
  • “Reconsidering the Economic Value of Multiple Sclerosis Therapies,” with C. Wakeford, D. Meletiche, J. Sussell, A. Chung, Y. Liu, J. Shim, and D. Lakdawalla, American Journal of Managed Care 22: 11, 2016.
  • “The Rising Burden of Preeclampsia bodog casino review United States Impacts Both Maternal and Child Health,” with D. Peneva, X. Xu, A. Sutton, E. Triche, R. Ehrenkranz, M. Paidas, and W. Stevens, American Journal of Perinatology 33: 4, 2016.
  • Podcast and Panel: “Big (Bad?) Data and the Healthcare Consumer,” 24th Annual Emerging Issues in Healthcare Law Conference, 10 March 2023